R&DParadigm Shift and Billion‐Dollar Biologics

Abstract

R&D success has been linked to the development and creation of billion‐dollar human medication. The blockbuster drugs are the main driver of industrial R&D and contribute a major share of the total pharmaceutical sales, profits, and market value of the successful companies. This article describes successes and failures of biotechnology R&D, criteria for blockbuster brands, global sales of biologics blockbuster brands, changing regulations, cost constraints, public‐private partnership to deliver and develop low‐cost treatments for tropical diseases, and information resources for biologics.